Hospitals in places across the United States have reimplemented mask mandates because of what officials say is an uptick in COVID-19 and other respiratory infections.
For example, the NYC Health + Hospitals—officially the New York City Health and Hospitals Corporation that operates public hospitals and clinics in New York City—announced that mask mandates will be reimplemented at its hospitals.
The post showed a photo of staff members wearing masks.
Other Mask Mandates
UMass Memorial Medical Center in Worcester, Massachusetts, confirmed to local media that it would issue a monthlong mask requirement for its staff, effective on Jan. 2. Patients and visitors won’t be mandated to wear face coverings, however.“These changes are expected to remain in effect for approximately one month, at which time they will be reevaluated based on current trends,“ a spokesperson for the hospital said in the statement. ”The health and wellbeing of our patients, visitors, and employees is our top priority.”
“Our masking policies are based on the current respiratory illness rates in our communities,” Mass General Brigham confirmed in a statement to local media on Dec. 28.
“Masks are not required but are strongly recommended for patients and visitors who do not have respiratory symptoms and are visiting low-risk areas of our medical facilities,” Kaiser Permanente’s guidance reads, according to the media outlet.
CDC Update
The CDC last week posted an update stating that the new COVID-19 variant, JN.1, makes up nearly half of all U.S. cases. Two weeks ago, it amounted to about 15 percent to 29 percent of all cases.JN.1 is continuing “to cause an increasing share of infections and is now the most widely circulating variant in the United States,” the agency stated, noting that the strain now accounts for about 39 percent to 50 percent of all COVID-19 cases.
It’s too early to tell whether JN.1 will cause an increase in infections or hospitalizations, according to the CDC. However, the World Health Organization (WHO) separately stated that JN.1 doesn’t appear to pose a high risk as compared with other variants, as it listed JN.1 as a “variant of interest.”
“The spread of this variant will unlikely increase the burden on national public health systems compared to other Omicron sublineages,” the WHO stated earlier in December. “However, countries approaching the winter season should be aware that, altogether, SARS-CoV-2 and co-circulating pathogens may exacerbate the respiratory disease burden.”
Symptoms of a JN.1 COVID-19 infection could include a cough, sore throat, fever, and headache, as well as muscle aches, loss of taste or smell, runny nose, brain fog, fatigue, muscle aches, and congestion, according to officials.
“As we observe the rise of the JN.1 variant, it’s important to note that while it may be spreading more widely, there is currently no significant evidence suggesting it is more severe or that it poses a substantial public health risk,” John Brownstein, chief innovation officer the Boston Children’s Hospital, told ABC News last week.